Micromet Release: New Study Supports Ep-CAM As Prime Target For Antibody Therapy In Common Cancers

The University of Basel, Switzerland, and Micromet AG have published a new study on the frequent high-level expression of antibody target epithelial cell adhesion molecule (Ep-CAM) in colon, lung, prostate and gastric cancers. The report has been published in the British Journal of Cancer (2006, 94: 128 – 135) (1). Ep-CAM is the target for Micromet's human antibody adecatumumab (MT201), which currently is in two phase II clinical trials in prostate and metastatic breast cancer, and is partnered with Serono.

Back to news